Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMROS5K)

Drug Name

TEPA (possesses cytotoxic activity) Drug Info

Synonyms

TEPA; Triethylenephosphoramide; Aphoxide; 545-55-1; Tris(1-aziridinyl)phosphine oxide; TAPO; Imperon fixer T; Triaziridinophosphine oxide; Triethylenephosphorotriamide; Triaziridinylphosphine oxide; Triethylene phophoramide; Triethylene phosphoramide; Phosphoric acid triethylene imide; Tris(1-aziridine)phosphine oxide; Triethylenephosphoric triamide; ENT 24915; Tris(aziridinyl)phosphine oxide; Tri-1-aziridinylphosphine oxide; Triethylenepyrophosphoramide; Tri(aziridin-1-yl)phosphine oxide; TEPA (VAN)

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 11016
ChEBI ID: CHEBI:82546
CAS Number: CAS 545-55-1
TTD Drug ID: DMROS5K

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Dopamine D1 receptor (D1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[3]
Pergolide	DM14MAE	Parkinson disease	8A00.0	Approved	[4]
Methylergonovine	DMBEX4O	Spontaneous abortion	JA00.0	Approved	[5]
Fenoldopam	DMFAOKP	Hypertension	BA00-BA04	Approved	[6]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[7]
Ecopipam	DMS9R43	Cocaine addiction	6C45.2	Phase 3	[8]
DAS-431	DMM3BPL	Dementia	6D80-6D86	Phase 2	[9]
Dihydrexidine	DMACPQO	Psychotic disorder	6A20-6A25	Phase 1/2	[10]
Lu AF28996	DMY572G	Parkinson disease	8A00.0	Phase 1	[11]
BAM-1110	DMPMKUF	Parkinson disease	8A00.0	Discontinued in Phase 2	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Glutathione S-transferase A1 (GSTA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[13]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[14]
Thiotepa	DMIZKOP	Breast cancer	2C60-2C65	Approved	[2]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[15]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[16]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[17]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[18]
Busulfan	DMXYJ9C	Chronic myelogenous leukaemia	2A20.0	Approved	[19]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[20]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[21]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Glutathione S-transferase P (GSTP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Busulfan	DMXYJ9C	Chronic myelogenous leukaemia	2A20.0	Approved	[22]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[23]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[24]
Chlorambucil	DMRKE63	Chronic lymphocytic leukaemia	2A82.0	Approved	[24]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[25]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[26]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[27]
Selenium	DM25CGV	N. A.	N. A.	Approved	[28]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[29]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[30]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cytochrome P450 2B6 (CYP2B6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[31]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[32]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[33]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[34]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[35]
Clopidogrel	DMOL54H	Acute coronary syndrome	BA41	Approved	[36]
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[37]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[38]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[39]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[40]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[41]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[42]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[43]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[44]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[45]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[45]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[46]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[47]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[48]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[49]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[41]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[42]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[47]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[47]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[50]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[51]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[52]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[53]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[55]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D1 receptor (D1R)	TTZFYLI	DRD1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 2B6 (CYP2B6)	OTOYO4S7	CP2B6_HUMAN	Regulation of Drug Effects	[2]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Regulation of Drug Effects	[2]
Cytochrome P450 3A5 (CYP3A5)	OTSXFBXB	CP3A5_HUMAN	Regulation of Drug Effects	[2]
Glutathione S-transferase A1 (GSTA1)	OTA7K5XA	GSTA1_HUMAN	Regulation of Drug Effects	[2]
Glutathione S-transferase P (GSTP1)	OTLP0A0Y	GSTP1_HUMAN	Regulation of Drug Effects	[2]

------------------------------------------------------------------------------------

References

1	N-(Iodopropenyl)-octahydrobenzo[f]- and -[g]quinolines: synthesis and adrenergic and dopaminergic activity studies. J Med Chem. 1998 Oct 8;41(21):4165-70.
2	Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. Br J Clin Pharmacol. 2009 Jan;67(1):50-60. doi: 10.1111/j.1365-2125.2008.03321.x. Epub 2008 Nov 17.
3	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
6	Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
7	Clinical pipeline report, company report or official report of Lundbeck.
8	A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
9	Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
10	trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
11	Clinical pipeline report, company report or official report of Lundbeck
12	Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.
13	Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. Int J Cancer. 2002 Feb 10;97(5):700-5.
14	Human glutathione S-transferase A (GSTA) family genes are regulated by steroidogenic factor 1 (SF-1) and are involved in steroidogenesis. FASEB J. 2013 Aug;27(8):3198-208. doi: 10.1096/fj.12-222745. Epub 2013 May 6.
15	Effects of phenytoin on glutathione status and oxidative stress biomarker gene mRNA levels in cultured precision human liver slices. Toxicol Sci. 2001 Jan;59(1):118-26.
16	Acetaminophen-induced hepatocyte injury: C2-ceramide and oltipraz intervention, hepatocyte nuclear factor 1 and glutathione S-transferase A1 changes. J Appl Toxicol. 2019 Dec;39(12):1640-1650. doi: 10.1002/jat.3881. Epub 2019 Aug 6.
17	Antineoplastic drug sensitivity of human MCF-7 breast cancer cells stably transfected with a human alpha class glutathione S-transferase gene. Cancer Res. 1991 Jan 15;51(2):587-94.
18	Establishment of cisplatin-resistant ovarian yolk sac tumor cells and investigation of the mechanism of cisplatin resistance using this cell line. Gynecol Obstet Invest. 2011;71(2):104-11. doi: 10.1159/000320744. Epub 2010 Dec 9.
19	Overexpression of glutathione S-transferase A1-1 in ECV 304 cells protects against busulfan mediated G2-arrest and induces tissue factor expression. Br J Pharmacol. 2002 Dec;137(7):1100-6. doi: 10.1038/sj.bjp.0704972.
20	Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
21	Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
22	Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2010 Dec 1;55(6):1172-9. doi: 10.1002/pbc.22739.
23	Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
24	The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J Pharmacol Exp Ther. 2000 Aug;294(2):480-7.
25	Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. 2004 Jun 15;64(12):4218-26.
26	Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
27	Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
28	Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
29	Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: Focus on functional proteomics. Toxicol Lett. 2017 Nov 5;281:26-34. doi: 10.1016/j.toxlet.2017.09.001. Epub 2017 Sep 5.
30	Glutathione S-transferase pi as a target for tricyclic antidepressants in human brain. Acta Biochim Pol. 2004;51(1):207-12.
31	Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
32	Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
33	Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
34	Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor. Chem Res Toxicol. 2014 Feb 17;27(2):304-308.
35	Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem. 2004 Jul 9;279(28):29295-301. doi: 10.1074/jbc.M400580200. Epub 2004 Apr 28.
36	Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3. Arch Toxicol. 2019 Aug;93(8):2247-2264. doi: 10.1007/s00204-019-02495-6. Epub 2019 Jul 16.
37	Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
38	Characterization of human cytochrome P450 induction by pesticides. Toxicology. 2012 Mar 29;294(1):17-26.
39	Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys. 2005 Feb 1;434(1):75-85.
40	Pyrethroids: cytotoxicity and induction of CYP isoforms in human hepatocytes. Drug Metabol Drug Interact. 2008;23(3-4):211-36.
41	The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
42	Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
43	Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
44	The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
45	Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
46	Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
47	Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
48	Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
49	Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
50	Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab Dispos. 2005 Jul;33(7):1074-81. doi: 10.1124/dmd.104.002279. Epub 2005 Apr 8.
51	Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
52	Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity. J Toxicol Sci. 2017;42(3):343-348.
53	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
54	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
55	Induction of hepatic CYP3A enzymes by pregnancy-related hormones: studies in human hepatocytes and hepatic cell lines. Drug Metab Dispos. 2013 Feb;41(2):281-90.